Study of Immune Thrombocytopenia Pathogenesis:

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

89 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-05-04

Study Completion Date

2015-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells. However, T cells are also involved but their role is not completely understood.

The aim of this study is to determine the implication of T cells in the pathogenesis of ITP, notably regulatory T cells (Treg, CD4+CD25highFoxp3+), cytotoxic T cells (CD3+CD8+) and T follicular helper cells (TFH, CD3+CD4+CXCR5+PD-1+ICOS+), in blood and in the spleen of primary ITP patients, compared to healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)

NCT02821572

Immune Thrombocytopenia

RECRUITING

Biologic Characterization of Patients With ITP

NCT05694325

Immune Thrombocytopenia

RECRUITING NA

Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura

NCT05093257

Immune Thrombocytopenic Purpura

UNKNOWN

Risk Factors for Thrombosis in Immune Thrombocytopenia

NCT03820960

Immune Thrombocytopenia

COMPLETED

French Adult Primary Immune Thrombocytopenia

NCT03429660

Thrombocytopenia

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immune Thrombocytopenia (ITP)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with ITP

Blood samples

Intervention Type OTHER

Spleen samples

Intervention Type OTHER

Controls

Blood samples

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples

Intervention Type OTHER

Spleen samples

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with ITP, defined as thrombocytopenia \< 30 G/L, once causes related to infection, medication, systemic auto-immune disease or malignant hemopathy have been ruled out
* persons who have provided written informed consent

Exclusion Criteria

* persons without national health insurance
* persons under 18 years old
* patients under guardianship
* pregnancy
* subjects suffering from a systemic auto-immune disease, cancer, a progressive infection, or treated with steroids or immunosuppressants.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes